HKU Scholars Hub: Browsing DSpace

Browsing by Author Lim, HY

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 8 to 14 of 14 < previous

	Title	Author(s)	Issue Date	Views
	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial Journal:Liver Cancer	Kudo, M Lim, HY Cheng, AL Chao, Y Yau, TCC Ogasawara, S Kurosaki, M Morimoto, N Ohkawa, K Yamashita, T Lee, KH Chen, E Siegel, AB Ryoo, BY	2020	38
	Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial Journal:Journal of Clinical Oncology	Finn, RS Ryoo, B-Y Merle, P Kudo, M Bouattour, M Lim, HY Breder, V Edeline, J Chao, Y Ogasawara, S Yau, T Garrido, M Chan, SL Knox, J Daniele, B Ebbinghaus, SW Chen, E Siegel, AB Zhu, AX Cheng, A-L The KEYNOTE-240 investigators	2020	95
	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma Journal:Clinical Cancer Research	Lim, HY Merle, P Weiss, KH Yau, TCC Ross, P Mazzaferro, V Blanc, JF Ma, YT Yen, CJ Kocsis, J Choo, SP Sukeepaisarnjaroen, W Gérolami, R Dufour, JF Gane, EJ Ryoo, BY Peck-Radosavljevic, M Dao, T Yeo, W Lamlertthon, W Thongsawat, S Teufel, M Roth, K Reis, D Childs, BH Krissel, H Llovet, JM	2018	50
	Randomised phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma Journal:Annals of Oncology	Kang, YK Yau, TCC Park, JW Lim, HY Lee, TY Obi, S Chan, SL Qin, S Kim, RD Casey, M Chen, C Bhattacharyya, H Williams, JA Valota, O Chakrabarti, D Kudo, M	2015	51
	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma Journal:Hepatology	Cheng, AL Thongprasert, S Lim, HY Sukeepaisarnjaroen, W Yang, TS Wu, CC Chao, Y Chan, SL Kudo, M Ikeda, M Kang, YK Pan, H Numata, K Han, G Balsara, B Zhang, Y Rodriguez, AM Zhang, Y Wang, Y Poon, RTP	2016	74
	Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study Journal:Journal of Clinical Oncology	Kelley, RK Sangro, B Harris, W Ikeda, M Okusaka, T Kang, YK Qin, S Tai, DWM Lim, HY Yau, T Yong, WP Cheng, AL Gasbarrini, A Damian, S Bruix, J Borad, M Bendell, J Kim, TY Standifer, N He, P Makowsky, M Negro, A Kudo, M Abou-Alfa, GK	2021	23
	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial Journal:ESMO Open	Kelley, RK Ryoo, BY Merle, P Park, JW Bolondi, L Chan, SL Lim, HY Baron, AD Parnis, F Knox, J Cattan, S Yau, T Lougheed, JC Milwee, S El-Khoueiry, AB Cheng, AL Meyer, T Abou-Alfa, GK	2020	29

Showing results 8 to 14 of 14 < previous